SCHEMBL257372

SCHEMBL257372

Cc1ccc(C(=O)c2ccc(F)cc2)s1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DAO P14920 1/20 0.57
NPC1 O15118 5/20 0.51
RAB9A P51151 5/20 0.51
SMN1; SMN2 Q16637 3/20 0.51
ALDH1A1 P00352 3/20 0.51
LTA4H P09960 1/20 0.44
KMT2A Q03164 3/20 0.43
MEN1 O00255 2/20 0.43
CES2 O00748 1/20 0.43
CES1 P23141 1/20 0.43
ADORA2A P29274 3/20 0.43
ADORA2B P29275 2/20 0.43
DUSP3 P51452 1/20 0.41
TDP1 Q9NUW8 2/20 0.41
POLB P06746 1/20 0.41
HSD11B1 P28845 1/20 0.41
KDM4E B2RXH2 1/20 0.41
HTT P42858 1/20 0.41
ESR1 P03372 1/20 0.41
CA1 P00915 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9147489 0.86 NPC1 (0.53) DAONPC1RAB9ASMN1; SMN2ALDH1A1
SCHEMBL24573401 0.83 DAO (0.64) DAOSMN1; SMN2ALDH1A1KMT2AADORA2A
SCHEMBL7392754 0.81 MAPT (0.57) DAONPC1RAB9ASMN1; SMN2ALDH1A1
SCHEMBL11403347 0.81 ALDH1A1 (0.66) DAONPC1RAB9ASMN1; SMN2ALDH1A1
SCHEMBL8308134 0.78 DAO (0.57) DAONPC1RAB9ASMN1; SMN2ALDH1A1
SCHEMBL15100864 0.75 MEN1 (0.52) DAONPC1RAB9ASMN1; SMN2ALDH1A1
SCHEMBL11704013 0.75 PTGS2 (0.60) DAOSMN1; SMN2ALDH1A1ADORA2AADORA2B
SCHEMBL11704001 0.75 PTGS2 (0.60) DAOSMN1; SMN2ALDH1A1ADORA2AADORA2B
SCHEMBL27938589 0.74 HPGD (0.46) DAONPC1RAB9ASMN1; SMN2ALDH1A1
SCHEMBL77302 0.73

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8895552-B2 Cyclic amide derivative SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) 2014-11-25 US disclosed
US-8895552-B2 Cyclic amide derivative SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) 2014-11-25 US disclosed
US-20130217692-A1 CYCLIC AMIDE DERIVATIVE DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2013-08-22 US disclosed
US-20130217692-A1 CYCLIC AMIDE DERIVATIVE DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2013-08-22 US disclosed
EP-2612848-A1 CYCLIC AMIDE DERIVATIVE Dainippon Sumitomo Pharma Co., Ltd. (JP) 2013-07-10 EP disclosed
WO-2012029942-A1 CYCLIC AMIDE DERIVATIVE 大日本住友製薬株式会社 (JP) 2012-03-08 WO disclosed
US-4064132-A ANTIINFLAMMATORY AGENTS JANSSEN PHARMACEUTICA N.V. (BE) 1977-12-20 US disclosed
US-4060528-A ANTIINFLAMMATORY JANSSEN PHARMACEUTICA N.V. (BE) 1977-11-29 US disclosed
US-4035376-A ESTERS, AMIDES, HYDROXAMIC ACIDS, ANTIINFLAMMATORY JANSSEN PHARMACEUTICA N.V. (BE) 1977-07-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130217692-A1 CYCLIC AMIDE DERIVATIVE HDAC10, H1-10, H1-0 DAO 2512/4885NPC1 1990/4885RAB9A 361/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.